[go: up one dir, main page]

ES2058602T3 - Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos. - Google Patents

Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos.

Info

Publication number
ES2058602T3
ES2058602T3 ES89912952T ES89912952T ES2058602T3 ES 2058602 T3 ES2058602 T3 ES 2058602T3 ES 89912952 T ES89912952 T ES 89912952T ES 89912952 T ES89912952 T ES 89912952T ES 2058602 T3 ES2058602 T3 ES 2058602T3
Authority
ES
Spain
Prior art keywords
alkaline
oxipurinol
salts
prepared
terrain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89912952T
Other languages
English (en)
Inventor
Wolfgang Lahr
Guido Weickgenannt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henning Berlin GmbH Chemie- und Pharmawerk
Original Assignee
Henning Berlin GmbH Chemie- und Pharmawerk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henning Berlin GmbH Chemie- und Pharmawerk filed Critical Henning Berlin GmbH Chemie- und Pharmawerk
Application granted granted Critical
Publication of ES2058602T3 publication Critical patent/ES2058602T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LAS PREPARACIONES DE OXIPURINOL Y/O DE SUS SALES DE ALCALI O DE ALCALITERREO EN UNA FORMA NO CRISTALIZADA CONTIENEN ACTIVADORES EN FORMA DE UNA DISPERSION DE MATERIA FIJA CON SUSTANCIAS AUXILIARES NO PENSADAS FARMACOLOGICAMENTE. TIENEN UNA ALTA Y RAPIDA SOLUBILIDAD SOBRE EL OXIPURINOL Y/O SUS SALES DE ALCALI O DE ALCALITERREO. SE PUEDEN UTILIZAR PARA LA ELABORACION DE MEDICAMENTOS CON UN ALTO GRADO DE LA SUSTANCIA OXIPURINOL.
ES89912952T 1988-11-25 1989-11-24 Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos. Expired - Lifetime ES2058602T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3839825A DE3839825A1 (de) 1988-11-25 1988-11-25 Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze

Publications (1)

Publication Number Publication Date
ES2058602T3 true ES2058602T3 (es) 1994-11-01

Family

ID=6367881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89912952T Expired - Lifetime ES2058602T3 (es) 1988-11-25 1989-11-24 Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos.

Country Status (5)

Country Link
EP (1) EP0445158B1 (es)
JP (1) JP2965689B2 (es)
DE (2) DE3839825A1 (es)
ES (1) ES2058602T3 (es)
WO (1) WO1990006115A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617612B1 (en) 1991-12-18 1997-09-10 Warner-Lambert Company A process for the preparation of a solid dispersion
DE4406462C2 (de) * 1994-02-24 1997-05-28 Jenapharm Gmbh Verfahren und Vorrichtung zur Herstellung fester Dispersionen
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2009118356A2 (en) * 2008-03-25 2009-10-01 Formac Pharmaceuticals N.V. Preparation method for solid disupersions
JPWO2016010093A1 (ja) * 2014-07-16 2017-04-27 株式会社セラバリューズ 非晶質クルクミン及び／又はその類縁体を含有する複合体の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975850A (en) * 1955-08-10 1964-11-18 Wellcome Found Xanthine oxidase inhibitors
GB1460302A (en) * 1973-05-23 1977-01-06 Wellcome Found Tablet formulation
DE2546371A1 (de) * 1975-10-16 1977-04-21 Sandoz Ag Neue galenische formen
EP0237348B1 (en) * 1986-03-13 1990-09-05 The Wellcome Foundation Limited Cell protection

Also Published As

Publication number Publication date
EP0445158A1 (de) 1991-09-11
DE3839825A1 (de) 1990-06-13
DE3839825C2 (es) 1992-04-16
JP2965689B2 (ja) 1999-10-18
JPH04502004A (ja) 1992-04-09
DE58905187D1 (de) 1993-09-09
EP0445158B1 (de) 1993-08-04
WO1990006115A2 (de) 1990-06-14
WO1990006115A3 (de) 1990-08-23

Similar Documents

Publication Publication Date Title
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
USD300790S (en) Stand for holding bananas
ES2098180B1 (es) Una composicion farmaceutica a base de compuestos de la clase de la rapamicina.
ES2058602T3 (es) Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
IT9020025A0 (it) Dispositivo per la somministrazione di sostanze medicamentose in polvere
DE58901934D1 (de) Verschlussanordnung fuer pharmazeutische flaschen.
IT1148238B (it) Dispositivo per la somministrazione di medicamenti in polvere
DE68901417D1 (de) Pharmazeutische zusammensetzung.
DE58909621D1 (de) TNF-Inhibitor enthaltendes Arzneimittel
ES2081102T5 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
ATE153538T1 (de) Transdermale therapeutische zubereitungen
DE69310887D1 (de) Pharmazeutische behälter und medizinische geräte mit hydrophilen, proteinverträglichen oberflächen
ES2179533T3 (es) Formulacion de medicamento con liberacion controlada del principio activo.
AR242907A1 (es) Dispositivo de doble punta para dosificar y suministrar medicamentos.
USD277297S (en) Container for desk top materials or similar articles
ITTO910061U1 (it) Complesso di supporto e di tenuta per l'inserimento tra due organi in rotazione relativa
DE69012031D1 (de) Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung.
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
IT8921567A0 (it) Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono.
USD274159S (en) Hypodermic syringe destruction and disposal device
USD320045S (en) Collapsible copy holder stand
ATE142880T1 (de) Penciclovir enthaltende pharmazeutische formulierung
USD328910S (en) Magnifier or similar article
AR195769A1 (es) Una composicion gelificada adecuada para su empleo en elementos de enfriamiento y articulo que la contiene

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 445158

Country of ref document: ES